[SCHEDULE 13G/A] Vor Biopharma Inc. Amended Passive Investment Disclosure
FMR reports 6.5% stake in Vor Biopharma
FMR LLC filed an amended Schedule 13G stating beneficial ownership of 2,526,170 shares of Vor Biopharma Inc. common stock, representing 6.5% of the class as of 12/31/2025.
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
FMR LLC filed an amended Schedule 13G stating beneficial ownership of 2,526,170 shares of Vor Biopharma Inc. common stock, representing 6.5% of the class as of 12/31/2025. Abigail P. Johnson is also reported as beneficial owner with sole dispositive power over the same shares.
The filing notes that one or more other persons, including Select Biotechnology Portfolio with 2,522,625 shares (6.5% of outstanding common stock as of 12/31/2025), have rights to receive dividends or sale proceeds. The securities are certified as held in the ordinary course of business without the purpose of influencing control.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What ownership stake does FMR LLC report in Vor Biopharma (VOR)?
FMR LLC reports beneficial ownership of 2,526,170 Vor Biopharma common shares, representing 6.5% of the outstanding class as of December 31, 2025. This stake gives FMR LLC sole dispositive power over those shares but no shared voting or dispositive authority.
How is Abigail P. Johnson reported in the Vor Biopharma Schedule 13G/A?
Abigail P. Johnson is listed as a reporting person with beneficial ownership of 2,526,170 Vor Biopharma common shares, or 6.5% of the class. She has sole dispositive power over these shares and no sole or shared voting power according to the disclosure.
Which other entity is mentioned as having an interest in Vor Biopharma shares?
The filing states that Select Biotechnology Portfolio has rights to receive dividends or sale proceeds from Vor Biopharma common stock. Its interest amounts to 2,522,625 shares, or 6.5% of total outstanding common stock as of December 31, 2025, under FMR LLC’s broader ownership structure.
What does the filing say about FMR LLC’s intent regarding control of Vor Biopharma?
The certification states the securities were acquired and are held in the ordinary course of business, not for changing or influencing control of Vor Biopharma. It also clarifies they are not held in connection with any transaction aimed at achieving such control, except limited nomination activities.
On what date is the Vor Biopharma ownership information in this Schedule 13G/A based?
The ownership information is based on an event date of December 31, 2025. As of that date, FMR LLC and Abigail P. Johnson each report beneficial ownership of 2,526,170 Vor Biopharma common shares, representing 6.5% of the company’s outstanding common stock.
Address or principal business office or, if none, residence:
245 Summer Street, Boston, Massachusetts 02210
(c)
Citizenship:
Not applicable
(d)
Title of class of securities:
COMMON STOCK
(e)
CUSIP No.:
929033207
Item 3.
If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)
Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)
Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)
Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)
Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)
An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)
An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)
A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)
A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)
A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)
A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
please specify the type of institution:
(k)
Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.
Ownership
(a)
Amount beneficially owned:
2526170.00
(b)
Percent of class:
6.5 %
(c)
Number of shares as to which the person has:
(i) Sole power to vote or to direct the vote:
Please see the responses to Items 5 and 6 on the cover page.
(ii) Shared power to vote or to direct the vote:
0.00
(iii) Sole power to dispose or to direct the disposition of:
2526170.00
(iv) Shared power to dispose or to direct the disposition of:
0.00
Item 5.
Ownership of 5 Percent or Less of a Class.
Not Applicable
Item 6.
Ownership of more than 5 Percent on Behalf of Another Person.
If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.
One or more other persons are known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the COMMON STOCK of VOR BIOPHARMA INC. The interest of Select Biotechnology Portfolio, in the COMMON STOCK of VOR BIOPHARMA INC, amounted to 2522625.00 shares or 6.5% of the total outstanding COMMON STOCK at 12/31/2025.
Item 7.
Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary.
See attached Exhibit 99.
Item 8.
Identification and Classification of Members of the Group.
Not Applicable
Item 9.
Notice of Dissolution of Group.
Not Applicable
Item 10.
Certifications:
By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
FMR LLC
Signature:
Stephanie J. Brown
Name/Title:
Duly authorized under Power of Attorney effective as of January 3, 2023, by and on behalf of FMR LLC and its direct and indirect subsidiaries*
Date:
02/04/2026
Abigail P. Johnson
Signature:
Stephanie J. Brown
Name/Title:
Duly authorized under Power of Attorney effective as of January 26, 2023, by and on behalf of Abigail P. Johnson**
Date:
02/04/2026
Comments accompanying signature: * This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on January 10, 2023, accession number: 0000315066-23-000003. ** This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on January 31, 2023, accession number: 0000315066-23-000038.
